Sangamo Therapeutics (NASDAQ:SGMO) Stock Price Up 9.8%

Sangamo Therapeutics Inc (NASDAQ:SGMO) rose 9.8% on Thursday . The stock traded as high as $10.56 and last traded at $10.55. Approximately 1,821,571 shares were traded during mid-day trading, a decline of 10% from the average daily volume of 2,018,201 shares. The stock had previously closed at $9.61.

SGMO has been the subject of several analyst reports. Wedbush set a $10.00 target price on Sangamo Therapeutics and gave the stock a “hold” rating in a research report on Sunday, March 10th. ValuEngine raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, April 26th. One analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $13.33.

The firm has a 50-day moving average price of $9.67. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.98 and a quick ratio of 3.98.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by ($0.14). Sangamo Therapeutics had a negative return on equity of 24.67% and a negative net margin of 113.03%. The company had revenue of $8.07 million during the quarter, compared to analysts’ expectations of $27.21 million. On average, analysts predict that Sangamo Therapeutics Inc will post -1.46 earnings per share for the current fiscal year.

In related news, CFO Kathy Yi sold 5,000 shares of the business’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $10.00, for a total value of $50,000.00. Following the transaction, the chief financial officer now owns 30,512 shares in the company, valued at $305,120. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.30% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. California Public Employees Retirement System lifted its stake in shares of Sangamo Therapeutics by 25.9% in the fourth quarter. California Public Employees Retirement System now owns 132,230 shares of the biopharmaceutical company’s stock worth $1,518,000 after acquiring an additional 27,200 shares in the last quarter. Tekla Capital Management LLC lifted its stake in shares of Sangamo Therapeutics by 40.5% in the fourth quarter. Tekla Capital Management LLC now owns 241,538 shares of the biopharmaceutical company’s stock worth $2,773,000 after acquiring an additional 69,649 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Sangamo Therapeutics by 8.0% in the third quarter. JPMorgan Chase & Co. now owns 105,711 shares of the biopharmaceutical company’s stock worth $1,792,000 after acquiring an additional 7,817 shares in the last quarter. Hsbc Holdings PLC acquired a new position in shares of Sangamo Therapeutics in the fourth quarter worth about $752,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Sangamo Therapeutics in the fourth quarter worth about $902,000. Institutional investors and hedge funds own 57.18% of the company’s stock.

Sangamo Therapeutics Company Profile (NASDAQ:SGMO)

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

Featured Article: How are Outstanding Shares Different from Authorized Shares?

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.